aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States.The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.
